Document is current
Any future updates will be listed below
-
Authors
Li, Fengzhi
Ling, Xiang
Chakraborty, Sayan
Tang, Dean G.
McLean, Karen
Wu, Wenjie
Sule, Norbert
Vadehra, Deepak
Fountzilas, Christos
Gupta, Ajay
Twist, Clare
Ohm, Joyce
Chatta, Gurkamal
Abrams, Scott I.
-
Funding
Funding for this research was provided by:
Pancreatic Cancer Action Network (20-65-FENG)
National Cancer Institute (R44CA176937)
National Cancer Institute (R44CA176937)
National Cancer Institute (R01CA237027)
National Cancer Institute (R01CA251198)
National Cancer Institute (R01CA250412)
- License Information
-
More Information
Article History
Received: 8 January 2026
Accepted: 6 May 2026
First Online: 18 May 2026
Declarations
:
: This review article contains both animal model data and human cancer cell line data. The animal model work was performed under the IACUC-approved protocol (1192 M) and the other in vitro work for the ethics approval are not applicable.
: The data provided in this review article are from the Authors’ research team and all authors agree to publish these data.
: FL118 and its core structure-based analogues will be further developed in Canget BioTekpharma LLC (www.canget-biotek.com), a Roswell Park Comprehensive Cancer Center (www.roswellpark.org) spinoff company. FL and XL are two of the eighteen initial investors to develop FL118 and its core structure-relevant anticancer agents. Other authors declare no conflicts of interest.
